OKTA vs. TVTX
OKTA (Okta, Inc.) and TVTX (Travere Therapeutics, Inc.) are both stocks. OKTA operates in Software - Infrastructure (Technology), while TVTX operates in Biotechnology (Healthcare). Over the past 5 years, OKTA returned -12.47%/yr vs 28.09%/yr for TVTX. At a 0.27 correlation, their price movements are largely independent.
Performance
OKTA vs. TVTX - Performance Comparison
Loading charts...
Returns By Period
The year-to-date returns for both investments are quite close, with OKTA having a 34.49% return and TVTX slightly higher at 36.19%.
OKTA
- 1D
- -1.03%
- 1M
- 48.71%
- YTD
- 34.49%
- 6M
- 28.95%
- 1Y
- 16.08%
- 3Y*
- 15.20%
- 5Y*
- -12.47%
- 10Y*
- —
TVTX
- 1D
- 6.40%
- 1M
- 16.81%
- YTD
- 36.19%
- 6M
- 49.41%
- 1Y
- 248.33%
- 3Y*
- 44.35%
- 5Y*
- 28.09%
- 10Y*
- 12.13%
OKTA vs. TVTX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
OKTA Okta, Inc. | 34.49% | 9.73% | -12.96% | 32.49% | -69.52% | -11.83% | 120.39% | 80.83% | 149.12% | 7.83% |
TVTX Travere Therapeutics, Inc. | 36.19% | 119.35% | 93.77% | -57.25% | -32.25% | 13.89% | 91.94% | -37.25% | 7.40% | 16.80% |
Correlation
The correlation between OKTA and TVTX is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.06 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.22 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.26 |
Correlation (All Time) Calculated using the full available price history since Apr 7, 2017 | 0.27 |
Over the past year, the correlation between OKTA and TVTX has dropped to 0.06 - well below their long-term average of 0.27, suggesting their price drivers have been diverging.
Fundamentals
OKTA:
$20.66B
TVTX:
$4.78B
OKTA:
$0.96
TVTX:
-$0.49
OKTA:
9.36
TVTX:
9.07
OKTA:
3.00K
TVTX:
48.42
OKTA:
$2.23B
TVTX:
$536.20M
OKTA:
$1.73B
TVTX:
$385.20M
OKTA:
$235.06M
TVTX:
$11.15M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
OKTA vs. TVTX — Risk / Return Rank
OKTA
TVTX
OKTA vs. TVTX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Okta, Inc. (OKTA) and Travere Therapeutics, Inc. (TVTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| OKTA | TVTX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.19 | ||
| Sortino ratioReturn per unit of downside risk | -3.33 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 1.53 | -0.42 |
| Calmar ratioReturn relative to maximum drawdown | 0.43 | 7.47 | -7.04 |
| Martin ratioReturn relative to average drawdown | 1.02 | 17.27 | -16.25 |
Loading charts...
Drawdowns
OKTA vs. TVTX - Drawdown Comparison
The maximum OKTA drawdown since its inception was -84.57%, roughly equal to the maximum TVTX drawdown of -85.43%. Use the drawdown chart below to compare losses from any high point for OKTA and TVTX.
Loading charts...
Drawdown Indicators
| OKTA | TVTX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -84.57% | -85.43% | +0.86% |
Max Drawdown (1Y)Largest decline over 1 year | -37.75% | -33.49% | -4.26% |
Max Drawdown (3Y)Largest decline over 3 years | -50.57% | -69.77% | +19.20% |
Max Drawdown (5Y)Largest decline over 5 years | -83.43% | -83.12% | -0.31% |
Max Drawdown (10Y)Largest decline over 10 years | — | -83.64% | — |
Current DrawdownCurrent decline from peak | -60.14% | 0.00% | -60.14% |
Average DrawdownAverage peak-to-trough decline | -38.27% | -41.07% | +2.80% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.82% | 14.46% | +1.36% |
Volatility
OKTA vs. TVTX - Volatility Comparison
Okta, Inc. (OKTA) has a higher volatility of 32.92% compared to Travere Therapeutics, Inc. (TVTX) at 16.06%. This indicates that OKTA's price experiences larger fluctuations and is considered to be riskier than TVTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| OKTA | TVTX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 32.92% | 16.06% | +16.86% |
Volatility (6M)Calculated over the trailing 6-month period | 48.12% | 52.58% | -4.46% |
Volatility (1Y)Calculated over the trailing 1-year period | 54.65% | 71.84% | -17.19% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 57.50% | 66.50% | -9.00% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 53.99% | 58.38% | -4.39% |
Dividends
OKTA vs. TVTX - Dividend Comparison
Neither OKTA nor TVTX has paid dividends to shareholders.
Financials
OKTA vs. TVTX - Financials Comparison
This section allows you to compare key financial metrics between Okta, Inc. and Travere Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
OKTA vs. TVTX - Profitability Comparison
OKTA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Okta, Inc. reported a gross profit of 595.00K and revenue of 765.00K. Therefore, the gross margin over that period was 77.8%.
TVTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Travere Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 127.20M. Therefore, the gross margin over that period was 0.0%.
OKTA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Okta, Inc. reported an operating income of 56.00K and revenue of 765.00K, resulting in an operating margin of 7.3%.
TVTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Travere Therapeutics, Inc. reported an operating income of -36.60M and revenue of 127.20M, resulting in an operating margin of -28.8%.
OKTA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Okta, Inc. reported a net income of 74.00K and revenue of 765.00K, resulting in a net margin of 9.7%.
TVTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Travere Therapeutics, Inc. reported a net income of -37.10M and revenue of 127.20M, resulting in a net margin of -29.2%.
Frequently Asked Questions
OKTA and TVTX have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
OKTA has higher volatility (32.92%) compared to TVTX (16.06%). In terms of maximum drawdown, OKTA dropped -84.57% vs TVTX's -85.43%.
TVTX currently has the higher Sharpe Ratio (3.48 vs 0.30), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for OKTA and TVTX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer